Komori
PhoenixBio (6190) · FactUpdate to full-year research and development expenses

Disclosure of R&D Expenditure

First written in FY2017-Q3. . Latest entry: FY2026.

32entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017-Q3 – FY20262017: 420172018: 420182019: 420192020: 420202021: 420212022: 420222023: 320232024: 220242025: 220252026: 12026
Same theme, other companies
Decrease in R&D expensesA theme 50 companies write about · 46 as a headwind · 4 as a tailwind

42 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 50 companies compared. The sentences above are computed from all 50.
Full recordFilings, disclosures and news, newest first
  1. FY2026Update to full-year research and development expensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥191.376 million.」

    Full-year research and development expenses amounted to ¥191.376 million, down from ¥273.750 million in the previous fiscal year. The policy of focusing on application development and the establishment of intellectual property rights continues.
  2. FY2026-H1Interim R&D Expense UpdateAnnual report

    「The amount of research and development activities for the Group as a whole during the current interim consolidated accounting period was ¥100.029 million.」

    Research and development activity expenses for the interim period were disclosed as ¥100.029 million, down from ¥148.095 million in the same period of the previous year. It was stated that there had been no material change in the status of research and development activities.
  3. FY2025Increase in full-year R&D expensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥273.750 million.」

    Full-year research and development expenses amounted to ¥273.750 million, up from ¥205.477 million in the previous fiscal year.
  4. FY2025-H1Higher interim-period R&D expensesAnnual report

    「The amount of research and development activities for the Group as a whole during the current interim consolidated accounting period was ¥148.095 million.」

    Research and development activity expenses for the interim period amounted to ¥148.095 million, up from ¥86.318 million in the same period of the previous year.
  5. FY2024-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥124.277 million.」

    Research and development activity expenses for the Group as a whole for the cumulative third quarter were disclosed as ¥124.277 million. It was stated that there had been no material change in the status of research and development activities.
  6. FY2024-Q1First-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥37.770 million.」

    Research and development activity expenses for the Group as a whole for the cumulative first quarter were disclosed as ¥37.770 million. It was stated that there had been no material change in the status of research and development activities.
  7. FY2023Update to full-year research and development expensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥205.477 million.」

    Full-year research and development expenses amounted to ¥205.477 million, down from ¥219.773 million in the previous fiscal year. The policy of focusing on application development and the establishment of intellectual property rights continues.
  8. FY2023-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥148.542 million.」

    Research and development activity expenses for the cumulative third quarter were disclosed as ¥148.542 million. It was stated that there had been no material change in the status of research and development activities.
  9. FY2023-Q2Second-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥96.158 million.」

    Research and development activity expenses for the cumulative FY2023-Q2 period were disclosed as ¥96.158 million. It was stated that there had been no material change in the status of research and development activities.
  10. FY2023-Q1First-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥44.986 million.」

    Research and development activity expenses for FY2023-Q1 were disclosed as ¥44.986 million. It was stated that there had been no material change in the status of research and development activities.
  11. FY2022Update to full-year research and development expensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥219.773 million.」

    Full-year research and development expenses amounted to ¥219.773 million, down from ¥221.115 million in the previous fiscal year. The policy of focusing on application development and the establishment of intellectual property rights continues.
  12. FY2022-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥136.459 million.」

    Research and development activity expenses for the cumulative third quarter were updated to ¥136.459 million. It was stated that there had been no material change in the status of research and development activities.
  13. FY2022-Q2Second-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥89.081 million.」

    Research and development activity expenses for the cumulative FY2022-Q2 period were disclosed as ¥89.081 million. It was stated that there had been no material change in the status of research and development activities.
  14. FY2022-Q1First-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥45.405 million.」

    Research and development activity expenses for FY2022-Q1 were disclosed as ¥45.405 million. It was stated that there had been no material change in the status of research and development activities.
  15. FY2021Update to full-year research and development expensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥221.115 million.」

    Full-year research and development expenses amounted to ¥221.115 million, down from ¥238.378 million in the previous fiscal year.
  16. FY2021-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥163.598 million.」

    Research and development activity expenses for the Group as a whole for the cumulative third quarter were disclosed as ¥163.598 million. It was stated that there had been no material change in the status of research and development activities.
  17. FY2021-Q2Second-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥115.755 million.」

    Research and development activity expenses for the Group as a whole for the cumulative second quarter were disclosed as ¥115.755 million. It was stated that there had been no material change in the status of research and development activities.
  18. FY2021-Q1First-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥57.333 million.」

    Research and development activity expenses for the Group as a whole for the cumulative first quarter were disclosed as ¥57.333 million. It was stated that there had been no material change in the status of research and development activities.
  19. FY2020Update to full-year research and development expensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥238.378 million.」

    Full-year research and development expenses amounted to ¥238.378 million, down from ¥345.585 million in the previous fiscal year.
  20. FY2020-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥168.733 million.」

    Research and development activity expenses for the Group as a whole for the cumulative third quarter were disclosed as ¥168.733 million. It was also stated that there had been no material change in the status of research and development activities.
  21. FY2020-Q2Second-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥105.579 million.」

    Research and development activity expenses for the Group as a whole for the cumulative second quarter were disclosed as ¥105.579 million. It was also stated that there had been no material change in the status of research and development activities.
  22. FY2020-Q1First-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥48.866 million.」

    Research and development activity expenses for the Group as a whole for the cumulative first quarter were disclosed as ¥48.866 million. It was also stated that there had been no material change in the status of research and development activities.
  23. FY2019Update to full-year research and development expensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥345.585 million.」

    Full-year research and development expenses amounted to ¥345.585 million, up from ¥176.120 million in the previous fiscal year.
  24. FY2019-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥219.324 million.」

    Research and development activity expenses for the Group as a whole for the cumulative third quarter were disclosed as ¥219.324 million.
  25. FY2019-Q2Second-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥128.501 million.」

    Research and development activity expenses for the Group as a whole for the cumulative second quarter were disclosed as ¥128.501 million.
  26. FY2019-Q1First-quarter R&D expenses updatedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥60.658 million.」

    Research and development activity expenses for the Group as a whole for the cumulative first quarter were disclosed as ¥60.658 million.
  27. FY2018Update to full-year research and development expensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥176.120 million.」

    Full-year research and development expenses amounted to ¥176.120 million, up from ¥140.642 million in the previous fiscal year.
  28. FY2018-Q3Update to third-quarter research and development expensesAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥121.859 million.」

    Research and development activity expenses for the Group as a whole for the cumulative third quarter were disclosed as ¥121.859 million.
  29. FY2018-Q2Disclosure of second-quarter research and development expensesAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative second quarter of the current consolidated fiscal year was ¥74.291 million.」

    Research and development activity expenses for the Group as a whole for the cumulative second quarter were disclosed as ¥74.291 million.
  30. FY2018-Q1First-quarter R&D expenditure disclosedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative first quarter of the current consolidated fiscal year was ¥32.881 million.」

    Research and development activity expenses for the Group as a whole for the quarter were disclosed as ¥32.881 million.
  31. FY2017Full-Year Disclosure of R&D ExpensesAnnual report

    「Research and development expenses for the current consolidated fiscal year related to the PXB mouse business and totaled ¥140.642 million.」

    The disclosure was updated from ¥108.173 million for the cumulative third quarter to full-year research and development expenses of ¥140.642 million.
  32. FY2017-Q3First statedAnnual report

    「The amount of research and development activities for the Group as a whole during the cumulative third quarter of the current consolidated fiscal year was ¥108.173 million.」

    Research and development activity expenses for the Group as a whole for the cumulative third quarter were disclosed as ¥108.173 million.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for PhoenixBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Disclosure of R&D Expenditure | PhoenixBio Co.,Ltd. (6190) | Komori